收盘价:Aug 18, 16:00:00 GMT-4
盘前:Aug 19, 05:20:52 GMT-4
No Data Yet
FDA approved Novartis's Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, based on PSMAddition trial data showing a 33% reduced risk of progression or death.
Novartis reported Q2 core operating profit that beat market expectations, driven by strong sales of cancer and multiple sclerosis drugs amid mounting generic competition.
Novartis AG 的当前价格为 $157.12,在上个交易日 下降 了 1.07%。
Novartis AG 属于 Pharmaceuticals 行业,该板块是 Health Care
Novartis AG 的当前市值是 $298.6B
据华尔街分析师称,共有 26 位分析师对 Novartis AG 进行了分析师评级,包括 5 位强烈买入,8 位买入,15 位持有,3 位卖出,以及 5 位强烈卖出